LITTLE GREEN PHARMA LIMITED (LGP)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

LGP

LGP - LITTLE GREEN PHARMA LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.55
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.12

02 Apr
2025

-0.005

OPEN

$0.13

-4.00%

HIGH

$0.13

74,711

LOW

$0.12

OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . MAP . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201820192020202220232024
EPS Basic xxxxxxxxxxxxxxx-2.7
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx25.6 M
Book Value Per Share xxxxxxxxxxxxxxx25.7
Net Operating Cash Flow xxxxxxxxxxxxxxx0.1 M
Net Profit Margin xxxxxxxxxxxxxxx-31.81 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-10.22 %
Return on Invested Capital xxxxxxxxxxxxxxx-9.75 %
Return on Assets xxxxxxxxxxxxxxx-8.82 %
Return on Equity xxxxxxxxxxxxxxx-10.22 %
Return on Total Capital xxxxxxxxxxxxxxx-14.04 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-0.6 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202220232024
Short-Term Debt xxxxxxxxxxxxxxx3 M
Long Term Debt xxxxxxxxxxxxxxx3 M
Total Debt xxxxxxxxxxxxxxx5 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx5 M
Price To Book Value xxxxxxxxxxxxxxx0.54

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202220232024
Capex xxxxxxxxxxxxxxx1.4 M
Capex % of Sales xxxxxxxxxxxxxxx5.63 %
Cost of Goods Sold xxxxxxxxxxxxxxx16 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx22 M
Research & Development xxxxxxxxxxxxxxx6 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

0
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

03/04/2025

1

Speculative Buy

$0.21

75.00%

Canaccord Genuity highlights Little Green Pharma is generating solid results with revenue in the nine months of FY25 exceeding FY24, and cash receipts up 90% y/y. The broker is forecasting positive free cash flow in FY26.

The broker notes the company is well-funded for growth plans, and the Health House acquisition is supporting the strategy of a vertically integrated model. 

Speculative Buy. Target unchanged at 21c.

FORECAST
Canaccord Genuity forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -0.80 cents.
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.50 cents.
Access Extra Coverage Research History >

LGP STOCK CHART

FNArena News on LGP

1
In Case You Missed It – BC Extra Upgrades & Downgrades – 25-10-24

Oct 25 2024 - Weekly Reports
2
In Brief: Aurum, Hillgrove & Little Green Pharma

Oct 25 2024 - Weekly Reports
3
Australian Broker Call *Extra* Edition – Oct 24, 2024

Oct 24 2024 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – Aug 01, 2024

Aug 01 2024 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – Apr 22, 2024

Apr 22 2024 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Behring Margin Outlook Still Main Game For CSL

Feb 13 2025 - Australia
2
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
3
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia
4
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024 - Small Caps
5
CSL Shares Breaking Free

Jul 23 2024 - Technicals
6
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps
7
‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024 - Australia
8
Twists And Turns Of Telix And Australian Biotech

Jul 10 2024 - Small Caps
9
Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024 - Small Caps
10
Dr Boreham’s Crucible: Island Therapeutics

Jun 17 2024 - Small Caps